Free Trial

Compass Therapeutics (CMPX) Stock Forecast & Price Target

Compass Therapeutics logo
$1.60 -0.09 (-5.03%)
Closing price 04:00 PM Eastern
Extended Trading
$1.59 -0.01 (-0.87%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Compass Therapeutics - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
0
Buy
9

Based on 9 Wall Street analysts who have issued ratings for Compass Therapeutics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 9 analysts, 8 have given a buy rating, and 1 has given a strong buy rating for CMPX.

Consensus Price Target

$11.63
624.30% Upside
According to the 9 analysts' twelve-month price targets for Compass Therapeutics, the average price target is $11.63. The highest price target for CMPX is $32.00, while the lowest price target for CMPX is $5.00. The average price target represents a forecasted upside of 624.30% from the current price of $1.61.
Get the Latest News and Ratings for CMPX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Compass Therapeutics and its competitors.

Sign Up

CMPX Analyst Ratings Over Time

TypeCurrent Forecast
4/3/24 to 4/3/25
1 Month Ago
3/4/24 to 3/4/25
3 Months Ago
1/4/24 to 1/3/25
1 Year Ago
4/4/23 to 4/3/24
Strong Buy
1 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
8 Buy rating(s)
7 Buy rating(s)
4 Buy rating(s)
2 Buy rating(s)
Hold
0 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$11.63$11.38$11.80$9.00
Forecasted Upside624.30% Upside309.17% Upside656.41% Upside386.49% Upside
Consensus Rating
Buy
Moderate Buy
Moderate Buy
Buy
Remove Ads

CMPX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CMPX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Compass Therapeutics Stock vs. The Competition

TypeCompass TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
3.11
2.81
2.54
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside624.30% Upside19,388.82% Upside25.02% Upside
News Sentiment Rating
Neutral News

See Recent CMPX News
Positive News
Positive News
Remove Ads
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
4/2/2025Guggenheim
2 of 5 stars
M. Schmidt
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$12.00 ➝ $12.00+451.72%
4/2/2025Leerink Partners
1 of 5 stars
Andrew Berens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$4.00 ➝ $6.00+167.86%
4/1/2025Leerink Partnrs
2 of 5 stars
A. Berens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
4/1/2025Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform$8.00+257.14%
4/1/2025D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Jason Kolbert
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$32.00 ➝ $32.00+1,584.20%
2/19/2025Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Biren Amin
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$12.00+278.55%
2/10/2025Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Maury Raycroft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$7.00 ➝ $8.00+105.13%
1/8/2025HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Joseph Pantginis
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00+464.97%
9/16/2024LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Huseynov
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$5.00+203.03%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 11:43 PM ET.


CMPX Forecast - Frequently Asked Questions

According to the research reports of 9 Wall Street equities research analysts, the average twelve-month stock price forecast for Compass Therapeutics is $11.63, with a high forecast of $32.00 and a low forecast of $5.00.

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Compass Therapeutics in the last twelve months. There are currently 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CMPX shares.

According to analysts, Compass Therapeutics's stock has a predicted upside of 624.30% based on their 12-month stock forecasts.

Over the previous 90 days, Compass Therapeutics's stock had 2 upgrades by analysts.

Compass Therapeutics has been rated by research analysts at D. Boral Capital, Guggenheim, HC Wainwright, Jefferies Financial Group, Leerink Partners, Leerink Partnrs, Piper Sandler, and Wedbush in the past 90 days.

Analysts like Compass Therapeutics more than other "medical" companies. The consensus rating for Compass Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how CMPX compares to other companies.


This page (NASDAQ:CMPX) was last updated on 4/3/2025 by MarketBeat.com Staff
From Our Partners